YU43002A - Metod za hemoprevenciju kancera prostate - Google Patents

Metod za hemoprevenciju kancera prostate

Info

Publication number
YU43002A
YU43002A YU43002A YUP43002A YU43002A YU 43002 A YU43002 A YU 43002A YU 43002 A YU43002 A YU 43002A YU P43002 A YUP43002 A YU P43002A YU 43002 A YU43002 A YU 43002A
Authority
YU
Yugoslavia
Prior art keywords
prostate cancer
chemoprevention
chemopreventive agent
prevents
prostate
Prior art date
Application number
YU43002A
Other languages
English (en)
Inventor
Mitchell Steiner
Sharan Raghow
Original Assignee
The University Of Tennessee Research Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Tennessee Research Corporation filed Critical The University Of Tennessee Research Corporation
Publication of YU43002A publication Critical patent/YU43002A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Ovaj pronalazak koji se odnosi na metodu za sprecavanje karcinogeneze prostate subjekta podrazumeva: davanje sisarskom subjektu farmaceutskog preparata koji sadrzi anti-estrogen ili njegov analog, derivat, izomer, i njegov metabolit; i njegove farmaceutski prihvatljive soli, estre ili N-okside, i njihove smese. Ovaj pronalazak se odnosi na metodu za suzbijanje ili inhibiranje latentnog kancera prostate subjekta koja podrazumeva: davanje sisarskom subjektu farmaceutskog preparata koji sadrzi anti-estrogen ili njegov analog, derivat, izomer, i njegov metabolit, i njihove farmaceutski prihvatljive soli, estre, ili N-okside, i njihove smese. Ovaj pronalazak se odnosi na smanjenje rizika za razvoj kancera prostate subjekta koja podrazumeva: davanje sisarskom subjektu farmaceutskog preparata koji sadrzi anti-estrogen, ili njegov analog, derivat, izomer, i njegov metabolit, i njihove farmaceutski prihvatljive soli, estre, ili N-okside, i njihove smese. Ovaj pronalazak se odnosi na metodu za povecanje verovatnoce prezivljavanja subjekta koji ima kancer prostate koja podrazumeva: davanje sisarskom subjektu farmaceutskog preparata koji sadrzi anti-estrogen ili njegov analog, derivat, izomer ili njegov metabolit i njihove farmaceutski prihvatljive soli, estre ili N-okside, i njihove smese. Ovaj pronalazak se odnosi na metodu lecenja subjekta koji ima kancer prostate, takvom da podrazumeva: davanje sisarskom subjektu farmaceutskog preparata koji sadrzi anti-estrogen ili njegov analog, derivat, izomer ili njegov metabolit i njihove farmaceutski prihvatljie soli, estre ili N-okside, i njihove smese. Ovaj pronalazak se odnosi na metodu za smanjenje kolicine prekanceroznih prekursora lezija adenokarcinoma prostate kod subjekta, koja podrazumeva: davanje sisarskom subjektu farmaceutskog preparata koji sadrzi anti-estrogen ili njegov analog, derivat, izomer i njegov metabolit, i njihove farmaceutski prihvatljive soli, estre ili N-okside, i njihove smese. U jednom nacinu primene antiestrogen je selektivni modulator receptora estrogena (SERM), trifeniletilen ili trifenilalkan. U jednom nacinu primene prekancerozni prekursor adenokarcinoma prostate je prostatna interaepitelialna neoplazija (PIN). U jednom nacinu primene prekancerozni prekursor adenokarcinoma prostate je prostatna intraepitelialna neoplazija visokog stepena (PIN). Prilozeni pronalazak omogucuje sigurnu i efektivnu metodu sprecavanja karcinogeneze prostate, suzbijajuci ili inhibirajuci latentni kancer prostate i posebno je korisna za lecenje subjekata koji imaju povisen rizik razvijanja kancera prostate, na primer, onih koji imaju benignu hiperplaziju, prostate, prostatnu interaepitelialnu neoplaziju (PIN), ili abnormalno visok nivo specificnog antitela prostate (PSA) u cirkulaciji, ili koji imaju kancer prostate u porodicnoj istoriji.
YU43002A 1999-11-08 2000-11-08 Metod za hemoprevenciju kancera prostate YU43002A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43620899A 1999-11-08 1999-11-08
US09/531,472 US6413533B1 (en) 1998-05-07 2000-03-20 Method for chemoprevention of prostate cancer

Publications (1)

Publication Number Publication Date
YU43002A true YU43002A (sh) 2005-09-19

Family

ID=27030854

Family Applications (1)

Application Number Title Priority Date Filing Date
YU43002A YU43002A (sh) 1999-11-08 2000-11-08 Metod za hemoprevenciju kancera prostate

Country Status (20)

Country Link
US (1) US6413533B1 (sh)
EP (1) EP1229903A4 (sh)
JP (1) JP2003513903A (sh)
KR (2) KR20060130788A (sh)
CN (1) CN1331463C (sh)
AU (1) AU782444B2 (sh)
BG (1) BG65794B1 (sh)
CA (1) CA2390295C (sh)
CZ (1) CZ20021763A3 (sh)
HK (1) HK1057000A1 (sh)
HR (1) HRP20020422A2 (sh)
HU (1) HUP0203304A3 (sh)
IL (1) IL149545A0 (sh)
IS (1) IS6375A (sh)
MX (1) MXPA02004676A (sh)
NO (1) NO20022221L (sh)
PL (1) PL354726A1 (sh)
SK (1) SK8162002A3 (sh)
WO (1) WO2001034117A1 (sh)
YU (1) YU43002A (sh)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20030130316A1 (en) * 2000-03-20 2003-07-10 Steiner Mitchell S. Method for chemoprevention of prostate cancer
CA2453337C (en) 2001-07-09 2012-08-28 Zonagen, Inc. Methods and materials for the treatment of testosterone deficiency in men
US7737185B2 (en) 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
US7524866B2 (en) * 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
CN1679956A (zh) 2001-11-29 2005-10-12 Gtx公司 治疗因雄激素剥夺引起的症状
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20040213841A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S Methods for treating hot flashes and gynecomastia
US20040096510A1 (en) * 2001-11-29 2004-05-20 Steiner Mitchell S. Prevention and treatment of androgen-deprivation induced osteoporosis
KR20030061474A (ko) * 2002-01-14 2003-07-22 한미약품 주식회사 서트랄린 제조용 중간체로서 사용되는 시스-라세메이트화합물의 개선된 제조방법
FI114917B (fi) * 2002-08-29 2005-01-31 Hormos Nutraceutical Oy Ltd Lignaanikomplekseja
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US7461048B2 (en) * 2003-07-21 2008-12-02 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US7467119B2 (en) * 2003-07-21 2008-12-16 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US7483554B2 (en) * 2003-11-17 2009-01-27 Aureon Laboratories, Inc. Pathological tissue mapping
US7070816B2 (en) * 2003-12-05 2006-07-04 New Chapter, Inc. Methods for treating prostatic intraepithelial neoplasia with herbal compositions
CA2557716A1 (en) * 2004-02-27 2005-09-15 Aureon Biosciences Corporation Methods and systems for predicting occurrence of an event
EP1776098A1 (en) * 2004-07-14 2007-04-25 Repros Therapeutics Inc. Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol
RU2413508C2 (ru) 2005-03-22 2011-03-10 Репрос Терапьютикс Инк. Режимы дозирования транс-кломифена
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
AU2007252991B2 (en) * 2006-05-22 2012-08-02 Hormos Medical Ltd. Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis
US9301987B2 (en) * 2007-09-24 2016-04-05 Laila Nutraceuticals Anti-adipogenic compositions containing Piper betle and Dolichos biflorus
ME00996B (me) 2007-10-16 2012-10-20 Repros Therapeutics Inc Trans-klomifen za liječenje metaboličkog sindroma
CN103221052A (zh) 2010-09-16 2013-07-24 施摩达生物技术有限公司 氟维司群组合物及使用方法
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
JP2015535283A (ja) 2012-11-02 2015-12-10 レプロス セラピューティクス インコーポレイティド 癌療法における使用のためのトランス−クロミフェン

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329364A (en) 1974-09-11 1982-05-11 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
US4474813A (en) 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
FI77839C (fi) 1982-05-27 1989-05-10 Farmos Oy Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat.
US5491173A (en) * 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
US5595985A (en) 1989-03-10 1997-01-21 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
US4990538A (en) 1989-08-23 1991-02-05 Harris Adrian L Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
GB9126209D0 (en) * 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
JP3566741B2 (ja) * 1992-10-27 2004-09-15 日本化薬株式会社 自己免疫疾患治療薬
DK0671909T3 (da) 1992-12-01 2001-03-19 Biotie Therapies Corp Syndecanstimulering af cellulær differentiering
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
CA2162586C (en) 1993-05-13 2006-01-03 David J. Grainger Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
EP0726772B1 (en) 1993-08-09 2001-11-07 Edward Baral A method for sensitization of cancer cells for killer cell mediated lysis
CA2143263C (en) * 1994-03-02 2002-01-08 Kerry John Hartauer Orally administrable raloxifene formulations
US5972383A (en) * 1994-03-02 1999-10-26 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5811120A (en) * 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5650425A (en) 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
US5821254A (en) * 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
US5635197A (en) 1995-03-21 1997-06-03 Eli Lilly And Company Treatment and prevention of prostatic cancer metastasis
US5629007A (en) 1995-03-21 1997-05-13 Eli Lilly And Company Method of preventing prostatic cancer development
DE19526146A1 (de) * 1995-07-07 1997-01-09 Schering Ag Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
US5728707A (en) * 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
US5726202A (en) * 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
US5883118A (en) * 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
US5859045A (en) * 1996-05-08 1999-01-12 Novo Nordisk A/S Novo Alle Crystalline -! 3R 4R-trans-7 methoxy 2,2-dimethyl1-3-phenyl 1-4 4-12 pyrrolidin-1 -Y1!ethoxyl 1!chromane hydrogen fumarate
DE69703294T2 (de) * 1996-05-22 2001-05-17 Protarga Inc Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten
ZA982819B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators.
ZA984650B (en) 1997-06-19 1998-12-08 Orion Corp Intratumoral administration of triphenylethylenes for the treatment of cancer
DE69840126D1 (de) * 1997-08-15 2008-11-27 Univ Duke Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
GB9805868D0 (en) * 1998-03-20 1998-05-13 Zeneca Ltd Anti-tumour agents
PL207462B1 (pl) * 1998-05-07 2010-12-31 Univ Tennessee Res Corp Zastosowanie związku trifenyloalkenowego
CA2346333A1 (en) * 1998-10-06 2000-04-13 Usda-Ars-Ott Compositions and methods of inhibiting neoplastic diseases with compounds related to limocitrin and 5-desmethyl sinensetin

Also Published As

Publication number Publication date
IL149545A0 (en) 2002-11-10
NO20022221L (no) 2002-06-28
HRP20020422A2 (en) 2004-04-30
CN1331463C (zh) 2007-08-15
KR20020070276A (ko) 2002-09-05
JP2003513903A (ja) 2003-04-15
KR100793721B1 (ko) 2008-01-10
EP1229903A4 (en) 2006-06-07
BG65794B1 (bg) 2009-12-31
WO2001034117A9 (en) 2002-05-10
HUP0203304A2 (hu) 2003-02-28
BG106738A (en) 2003-02-28
US6413533B1 (en) 2002-07-02
CZ20021763A3 (cs) 2003-02-12
KR20060130788A (ko) 2006-12-19
CN1420765A (zh) 2003-05-28
AU1588401A (en) 2001-06-06
IS6375A (is) 2002-05-08
SK8162002A3 (en) 2003-03-04
PL354726A1 (en) 2004-02-09
EP1229903A1 (en) 2002-08-14
HUP0203304A3 (en) 2006-02-28
HK1057000A1 (en) 2004-03-12
WO2001034117A1 (en) 2001-05-17
CA2390295A1 (en) 2001-05-17
MXPA02004676A (es) 2004-09-10
CA2390295C (en) 2009-09-29
NO20022221D0 (no) 2002-05-08
AU782444B2 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
YU43002A (sh) Metod za hemoprevenciju kancera prostate
YU3902A (sh) Imidazoimidazoli i triazoli kao anti-inflamatorna sredstva
AU1270599A (en) Radioactive embolizing compositions
MX9702865A (es) Agentes estrogenicos.
MY137766A (en) Exemestane as chemopreventing agent
TW200637831A (en) Triazole compounds that modulate Hsp90 activity
AU3652102A (en) Compounds and their uses
WO2001071022A3 (en) Lpa receptor agonists and antagonists and methods of use
BR9914163A (pt) Agente para melhorar a potência excretora da bexiga urinária, uso de um composto de amina do tipo não carbamato que tenha uma ação inibidora de acetilcolinesterase, e, método para melhorar a potência excretora da bexiga urinária
HK1040983A1 (en) Quinones for treatment of diseases.
GB0002336D0 (en) Medicaments
GB2340751B (en) Pharmaceutical compositions
MY121523A (en) Resorcinol derivatives
GB9907571D0 (en) Compounds
WO2002020000A3 (en) Combined estrogen blockade of the breast with exemestane and raloxifene
AP1413A (en) Rescorcinol composition.
MXPA03008946A (es) Metodos para sintetizar compuestos que contienen fenol.
MXPA03005374A (es) Carbazoles antitumorales.
BR0017046A (pt) Uso de azóis para prevenção de câncer de pele
HK1085744A1 (en) Steroid compounds with anti-tumor activity
WO2000037065A3 (en) Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs
YU31499A (sh) Proces za dobijanje jedinjenja pirolidinil hidroksamske kiseline
EA200200555A1 (ru) Способ химиопрофилактики рака предстательной железы
AU9399898A (en) Benzothiophenes
ZA200400824B (en) Pyridin-2-yl-methlyamine derivatives for treating opioid dependence.